检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Atezolizumab (ATEZO) plus Bevacizumab (BEV) vs Sorafenib (SOR) in Patients (PTS) with Unresectable Hepatocellular Carcinoma (HCC): Phase 3 Results from Imbrave150

Peter R Galle, Ann-Lll Cheng,Shukui Qin,Masafumi Ikeda,Michel Ducreux,Andrew Zhu,Tae-You Kim,Masatoshi Kudo,Valeriy Breder,Philippe Merle,Ahmed Kaseb,Daneng Li,Wendy Verret, Derek Xu,Sairy Hernandez,Juan Liu,Hui Shao,Sohail Mulla,Hy Lim,Richard Finn

ONCOLOGY RESEARCH AND TREATMENT（2020）

引用 0|浏览7
暂无评分
关键词
unresectable hepatocellular carcinoma,bevacizumab,sorafenib,atezolizumab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要